BLA 125557 · Amgen
Blincyto
Blinatumomab · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 3, 2014
Approved uses
9
Original approval plus efficacy supplements
Registered trials
176
30 Phase 3, 59 recruiting
FAERS reports
10,722
8,619 serious, 1,935 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ] . Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning....
What it is approved for
From the label in effect Apr 14, 2026.
BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 ) 1.1 MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older. 1.2 Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older. 1.3 B-cell Precursor ALL in the Consolidation Phase BLINCYTO is indicated for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older.
Mechanism: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, which result in redirected lysis of CD19+ cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2024 Supplement 28 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jun 20, 2023 Supplement 23 · Efficacy OrphanLabelLetter
- Jun 20, 2023 Supplement 26 · Efficacy · priority review OrphanLabelLetter
- Mar 11, 2021 Supplement 18 · Efficacy · priority review Orphan
- Mar 11, 2021 Supplement 20 · Efficacy · priority review LabelLetter
- Mar 29, 2018 Supplement 13 · Efficacy · priority review OrphanLabelLetterReview
- Jul 11, 2017 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- Aug 30, 2016 Supplement 5 · Efficacy · priority review OrphanLetterLabelReview
- Dec 3, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelReviewPediatric Medical Review
1 products under this application
- BLINCYTO · BLINATUMOMAB 35MCG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Blinatumomab" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06882057 · 3,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 31, 2029
Drug: Blinatumomab; Reinduction-2 omission and 1 more · For: Acute Lymphoblastic Leukemia ALL; Childhood Leukemia, Acute Lymphoblastic; B Cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Hefei, China; Chongqing, China; Fuzhou, China · 27 sites in all
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06764238 · 1,800 participants (planned) · Start Jan 3, 2025 · Primary completion Dec 31, 2029
Drug: Blinatumomab (Group A); Venetoclax (nonRand Group) and 1 more · For: Acute Lymphoblastic Leukemia ALL; Childhood Leukemia, Acute Lymphoblastic; B Cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 27 sites in all
- NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALLPivotal-lookingNot yet recruiting
The Children's Hospital of Zhejiang University School of MedicineAcademic, hospital or other
NCT06763302 · 1,220 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2027
Drug: Blinatumomab · For: B Cell Precursor Acute Lymphoblastic Leukemia; Pediatric; Minimal Residual Disease and 1 more
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06860269 · 1,200 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2035
Drug: Randomization + Blinatumomab + chemotherapy; Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone and 1 more · For: Acute Lymphoblastic Leukemia
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia1,187
- cytokine release syndrome1,150
- acute lymphocytic leukaemia recurrent1,121
- off label use793
- death674
- neurotoxicity584
- drug ineffective448
- headache379
- neutropenia333
- febrile neutropenia313
- therapy non-responder291
- tremor287
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 8 |
| 2015 | 446 |
| 2016 | 712 |
| 2017 | 808 |
| 2018 | 803 |
| 2019 | 865 |
| 2020 | 789 |
| 2021 | 1,013 |
| 2022 | 959 |
| 2023 | 1,100 |
| 2024 | 1,297 |
| 2025 | 1,065 |
| 2026 | 857 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Blincyto (Blinatumomab)
2024 spending
$1.7M
Beneficiaries
n/a
48 claims
Per beneficiary
n/a
$5,125.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,119,120 |
| 2021 | $2,005,937 |
| 2022 | $1,327,683 |
| 2023 | $1,523,068 |
| 2024 | $1,704,009 |
Part B: Blincyto (Blinatumomab) · HCPCS J9039
2024 spending
$86.2M
Beneficiaries
357
3,233 claims
Per beneficiary
$241,533
2024 ASP limit $148.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $24,174,501 |
| 2021 | $27,936,547 |
| 2022 | $34,078,269 |
| 2023 | $73,167,103 |
| 2024 | $86,227,273 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta S, Rau RE, Kairalla JA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Litzow MR, Sun Z, Mattison RJ, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II
- Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.